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Although life-threatening ventricular dysrhythmias are uncommon in young
patients, there are underlying heart diseases that may predispose these pa-
tients to ventricular tachycardia or ventriCUlar fibrillation (VT\VF). To test the
hypothesis that tiered therapy with a pacemaker-cardioverter defibrillator
(PCD) is a therapeutic option for young patients at risk for sudden death,
we reviewed our experience with these devices. Nine patients. aged 9-33
years (17.7 ± 7, mean ± SO) at the time of implantation, received PCD's
between March, 1993, and the present. Post-operative diagnoses included
complete repair of tetralogy of Fallot (2), Senning for D-transposition of the
great arteries (1), double outlet right ventricle, status post ventricular septal
defect closure baffling the left ventricle to the aorta (1), and Fontan for sin-
gle ventricle with pulmonary stenosis (1). Other diagnoses included Wolff-
Parkinson-White (WPW) (1), WPW and dilated cardiomyopathy (1). arrhyth-
mogenic right ventricular dysplasia (1). and long OT syndrome (1). All pa-
tients had inducible or clinical unstable VT\VF before implantation except
one patient with WPW who had a family history of sudden death. Seven of
the patients had failed antiarrhythmics before implantation. Defibrillator elec-
trode configurations consisted of epicardial patches (4), transvenous alone
(3). and transvenous with subcutaneous patch(es) (2). In 10.4 ± 5 (range 2-
17) months of follow-up, overdrive pacing was successful in one patient, and
there have been appropriate defibrillator discharges in five patients (56%).
Seven of the nine patients remain on antiarrhythmics. There was only one
complication, a moderate pericardial effusion two months following transve-
nous lead implantation in a 24.9 kg nine-year old. No system has required
revision to date.
Conclusion: In relatively short-term follow-up over 50% of our patients
successfully have used tiered therapy from pacemaker-cardioverter defib-
rillators. This implies that these therapies protect selected young patients
from sudden cardiac death, potentially greatly increasing their life span.
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cured by a median of 7 RFC applications. Procedure duration was 3.4 ± 1.9
hours. with a median radiation exposure time of 29.0 minutes. During a 19
month follow-up (median), 20/22 infants were asymptomatic and required no
antiarrhythmic medication. Two pts had recurrences of SVT (1 PJRT). one of
which underwent a successful repeat session. Tachycardia related reduced
left ventricular function evolved to normal values in all 3 infants within the
follow-up period. There were no serious complications.
Conclusions: 1) RFC-ablation of accessory pathway-mediated supraven-
tricular tachycardia is feasible, safe and effective in children aged less than
6 years. 2) Reduced invasiveness due to simplified catheter techniques is
achievable in this particular patient population. 3) In children with an age <6
years, indication for RFC-ablation is restrictive and should be provided in pts
with severe symptoms due to drug-refractory SVT.
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To further examine the outcome of Fontan pts with pacemakers we evalu-
ated our database of 500 consecutive pts who underwent a Fontan operation
at Children's Hospital in Boston between April, 1973 and August 1991 (mean
follow up 3.5 ± 3.9 yrs, range 0-20.2 yrs). Pacemakers were implanted in 47
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Permanent Overdrive Atrial Pacing in Chronic
Management of Atrial Reentrant Tachycardias in
Postoperative Patients with Congenital Heart
Disease
Children Below 6 Years of Age with Accessory
Pathway Related Tachyarrhythmlas. Whom to
Ablate and How
Risk Factors for Venous Obstruction in Children
with Transvenous Pacing Leads
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To determine the incidence and risk factors for venous obstruction (OBST).
we prospectively evaluated with echocardiography 63 of 70 eligible children
who had transvenous pacing leads placed between 1985 and 1993. The me-
dian (range) age at initial implantation was 7.6 yrs (0.7, 16). and 8 patients
had subsequent additional implants. OBST was defined as a combination
of Doppler flow abnormalities in the SVC or innominate (InnV) vein and a
20 echo appearance of vessel narrowing andlor the clinical appearance of
dilated superficial veins. OBST was noted in 13/63 (21 %) patients, with loca-
tion of 08ST at the distal SUbclavian vein in 5, SVC in 4, InnV-SVC junction
in 2, and multiple sites in 2. Venography in 11 of these patients (2 refused)
showed that the severity of 08ST (as defined by % luminal narrowing) was
complete (100%) in 3 patients, severe (>90%) in 4, and moderate (60--90%)
in 4. Of the 8 patients who had additional implants, 3 (38%) had 08ST. Risk
factors for OBST in the remaining 55 single implant patients (10 with OBST;
18%) were explored. Patients with vs. without 08ST did not differ regarding
date or duration of implant, number of leads, lead material or the presence
of associated heart defects Or surgery. Patients with OBST were younger at
implant (median 5.6 vs. 8.8 yrs; p < 0.05). Total cross-sectional area of lead(sl
was related to body surface area at implant (RATIO). Patients with OBST had
higher mean RATIO (7.6 ± 1.6 mm 2 /m 2 ) than patients without 08ST (4.9
± 2.0 mm2 /m 2 ; p < 0.0002). After controlling for RATIO in multiple logistic
regression, no other variable predicted 08ST. Receiver-operator character-
istic curves showed a RATIO of >6.6 mm2/m 2 to best predict OBST, with a
sensitivity of 90% and specificity of 84%.
Conclusion: Since pacing is lifelong, sizing of transvenous leads to the
child is important to prevent 08ST and preserve venous access.
Joachim Hebe, Christian Weif?" JOrgen Siebels, Matthias Antz, Riccardo Cappato.
Thomas Meinertz, Karl H. Kuck. Department of Cardiology, University Hospital.
Eppendorf, Germany; SI. Georg Hospital, Hamburg. Germany
By August 1994, a total of 103 children (:s15 yrs) underwent radio-frequency
current (RFC) ablation for accessory pathway (AP) mediated supraventricu-
lar tachycardia (SVT). Of these, 23 were infants aged less than 6 years (11
f, 12 m; 3.9 ± 1.6 yrs). All infants had suffered from recurrent or almost in-
cessant episodes of SVT, which were diagnosed at birth in 13 and prenatally
in 4. SVT was refractory to an antiarrhythmic regimen with 3 to 6 different
agents. Tachycardia-related symptoms included cardiac arrest in 2 infants
with WPW, syncope in 3 pts, reduced physical stress capacity in 11 and
SVT-related chest pain in 1. Thirteen pts had an overt AP. with an additional
concealed pathway in 2; the remaining 10 pts had a concealed Ap' in 6 of
which it sustained the permanent form of junctional reciprocating tachycar-
dia (PJRT). In the latter group 3 infants had reduced left ventricular function
(Fraction-shortening 13 to 21). In 11 infants, a single 5- or 6 French steerable
catheter was used for therapeutic intervention. In 9 infants a second catheter
was required for diagnostic purposes. Within 25 sessions. 22 infants were
Pietro Ragonese. Fabrizio Drago. Department of Pediatric Cardiology Bambino Gesu
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Sustained atrial tachycardias occurring after surgery for congenital heart dis-
ease. are often difficult to control by antiarrhythmic drugs and byantitachy-
cardia pacing. We implanted a permanent pacing system in 11 pts with drug
resistant recurrent atrial reentrant tachycardias. 7 pts were male and 4 fe-
male; mean age was 7.4 years (range 1 to 28 yrs); mean time from surgery
to the first documented atrial tachycardia was 2.2 years (range 1 month to 9
yrs). All pts had been unsuccessfully treated with two to five antiarrhythmic
drugs before pacing. At implantation the atrial pacing rate was programmed
to be 20% faster than the mean diurnal spontaneous rate. Individualized pro-
grams of pacemaker rate settings were then selected following serial 24
hours Holter monitoring, to obtain a prevailing paced atrial rhythm. Mean
follow-up was 3.4 years (range 6 mos to 5 yrs). 3 pts had recurrences of atrial
tachycardia during the first six months after the implantation, 8 pts remained
arrhythmia free. No patient had late recurrences and only two are still on an-
tiarrhythmic drug therapy. In conclusion: permanent overdrive atrial pacing
is a very useful tool in chronic management of postoperative atrial reentrant
tachycardias.
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The Prognostic Value of Pharmacological
Stress-Echocardiography: Experience in a
Primary Care Cardiology Center
To assess the intercenter agreement in the interpretation of dobutamine
stress echocardiograms (DSE), 5 experienced centers were each asked to
submit 30 DSE (dobutamine up to 40 mcgjkg/min and atropine up to 1 mg)
performed on patients (pts) with suspected coronary artery disease (CAD)
undergoing coronary angiography. Thus, a total of 150 DSE were interpreted
by each center unaware of any other patient data apart from the echos (no
data on maximal dosage and reason for termination of DSE). No case was
excluded due to low image quality or inadequate stress level. Data acquisi-
tion was performed in quad-screen format by 3 centers and on video tape
by 2 centers.
Coronary angiography proved CAD in 95 pts (>50% diameter stenosis).
Agreement in specific segments ranged from 84% to 97%, being highest for
the basal anteroseptal segment and lowest for the basal inferior segment.
On a patient basis, 4/5 or 5/5 of the five centers agreed on DSE abnormality
or normality in 73%. Agreement was higher in pts with no CAD (82%; n =
55 pts) and in pts with 3 vessel disease (100%; n = 14 pts), and lower in pts
with 1 and 2 vessel disease 161 and 68%, respectively).
Conclusion: Although there was heterogeneity in data acquisition, over-
all intercenter agreement in interpretation of stress echocardiograms is ac-
ceptable and comparable to similar data from perfusion scintigraphy. To in-
crease intercenter agreement, a better standardization in image acquisition
and reading criteria of stress echocardiography is warranted.
Lauro Cortigiani, Massimo Lombardi, Emilio Paolini, Daniele Nosari,
PierRomano Mariani, Eugenio Nannini. u.o. Cardiologia, Ospedale Castelnuovo
Garfagnana. Italy
Aim of the study was to evaluate the value of pharmacological stress
echocardiography for risk stratification and clinical decision making in a pri-
mary care cardiology center.
A population of 526 patients (270 males and 256 females, age 60 ± 1oyear,
mean ± SO) with evidence, or suspected coronary artery disease were stud-
ied by pharmacological stress-echo. Patients underwent either Dipyridamole
stress-echo (DIP) up to 0.84 mglkg, or Dobutamine stress-echo (DaB) up to
40 j.Lg/kg/min. Criteria for positivity of each test were an increase in wall mo-
tion score index during stress compared to pre-test, in a 16 segments model
of left ventricle, each segment ranging from 1 = normal to 4 = diskinetic. DIP
was performed in 398 patients and DOB in 128 patients. DIP was positive in
Intercenter Agreement in Interpretation of
Dobutamine Stress Echocardiograms. A
Multicenter Trial
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bicin. Changes in LV structure and function adjusted for age or body surface
area at 3 time points were compared: prior to doxorubicin (A), 6.4 years after
doxorubicin (B), and 11.1 years after doxorubicin (C). LV fractional shortening
fell from normal at A to significantly depressed at B, and remained stable but
depressed at C. LV mass was normal for body surface area at A, below nor-
mal at B, and continued to become more abnormal at C (p = 0.001). LV wall
thickness was normal for body surface area at A below normal at B, and con-
tinued to become more abnormal at C (p = 0.03). LV end-diastolic dimension
was normal for body surface area at A and B, but during the subsequent 4.7
years, a significant fall in LV end-diastolic dimension for body surface area
occurred (p = 0.03). LV afterload increased significantly from A to B, but
remained elevated without further increase at C. LV contractility remained
normal at all 3 times. In conclusion, the fall in LV dimension to subnormal
levels with increasing follow-up, in spite of a reduced mass:volume ratio,
is the pattern seen in restrictive cardiomyopathy with a loss of the capacity
of the LV to dilate. Both the echocardiographic and clinical findings suggest
that the moderate to long term course of children treated with boluses of
doxorubicin may follow the clinical findings of a restrictive cardiomyopathic
process with decreased LV compliance and a small thin-walled LV
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Verapamil Therapy in Infants with Hypertrophic
Cardiomyopathy
pts 11 0%), 10 priorto Fontan, 3 at the time of Fontan, and 34 post Fontan.lndi-
cations for pacemaker implantation included sinus node dysfunction (SND)
(n = 8), atrio-ventricular block (AVB) (n = 22), atrial flutter with (n = 13) or
without (n = 2) coexisting SND, or SND and AVB (n = 2). Pacing modes in-
cluded 9 with single chamber ventricular pacing (WI), 19 with dual chamber
pacing (DOD), and 19 with atrial pacing (AAI), of which 8 have antitachycardia
pacing capability. Since 1983, most pts (90%) >2 yrs old with CHB received
DOD pacing. The Kaplan-Meier survival curve compares the various pacing
modes to non-paced pts.
Long term survival with a Fontan was significantly worse in pts with VVI
pacemakers compared to the other groups, but those pts with WI pacing
were younger at the time of Fontan surgery or had earlier date of surgery.
Outcome in AAI and DOD paced pts was similar to non-paced pts. "Phys-
iologic" pacing IAAI or DOD) is preferable for single ventricle pts having a
Fontan operation who require a pacemaker.
Left Ventricular Structure and Function Eleven
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Leukemia: Is this a Restrictive Cardiomyopathic
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The safety and efficacy of verapamil therapy in infants with hypertrophic car-
diomyopathy (HCM) was prospectively evaluated in 17 children presenting
at age 2 days to 1 year (median 3.5 months) with primary HCM (asymmetric
or regional hypertrophy excluding infants of diabetic mothers, and metabolic
disorders). Acute response to intravenous verapamil infusion was assessed
during cardiac catheterization. Effects of chronic therapy were assessed by
clinical, echocardiographic, and Holter monitor evaluation.
At presentation, 10 of 17 were symptomatic 17 congestive heart failure, 4
cyanosis, 1 arrhythmia, 1 apnea). Three cases were diagnosed on prenatal
ultrasound. There was a positive family history in 7/15,16/17 had murmurs,
all had abnormal ECGs, 6 had weight >5%ile, and 2 had Noonan's syndrome.
Acute verapamil infusion was well tolerated by all, without adverse elec-
trophysiologic effects. Hemodynamic effects of verapamil were consistent
with a negative inotropic effect with a significant fall in cardiac index (4.6
± 1.2 to 4.0 ± 0.7 i/min/m2), no change in end-diastolic pressure (15 ± 8
mmHg before to 15 ± 6 mmHg after), and a small fall in systolic blood pres-
sure (mean -7 mmHg). In the 8 patients with LV outflow obstruction, the LV
to aortic gradient decreased by -18 mmHg mean (range +1 to -45). Fol-
lowup is not available in 1 of 17 patients. Two patients underwent surgery
for subaortic stenosis. During 1 to 116 months (mean 32 months) of oral
verapamil therapy, two patients died (one sudden, one after cardiac trans-
plant). The sudden death occurred during Holter monitoring and appeared
unrelated to verapamil. Complete heart block was seen transiently in one but
other significant electrophysiologic side effects were not observed. Among
the 14 survivors with followup, 6 are clinically and echocardiographically im-
proved, 8 are stable, and none have had clinical deterioration or worsening
disease on echocardiography. Echocardiographically, LV outflow obstruction
decreased in 8/10 patients, remained unchanged in 1, and increased in the
patient who subsequently underwent cardiac transplantation. Two patients
have had complete resolution of hypertrophy on echocardiogram.
We found that verapamil was well tolerated in infants with HCM without
evidence of adverse effects and outcome was considerably better in these
patients compared with prior reports. Resolution of hypertrophy in some pa-
tients suggests that either reversal of the phenotypic expression of this dis-
order is possible or else clinical and echocardiographic criteria may result in
misdiagnosis.
We previously characterized the progressive abnormalities of left ventricular
(LV) structure and function in 115 survivors of childhood acute lymphoblastic
leukemia 6.4 years (mean) after completion of doxorubicin therapy. 65% of
patients having received >228 mg/m2 of doxorubicin had either increased af-
terload or decreased contractility, or both. Progressive increases in afterload
due to a thin LV wall appeared related to an inability to increase LV mass in
response to somatic growth. Of these 115 patients, 36 have died, relapsed,
or are no longer followed at our institution. 8 patients had both early and
late congestive heart failure Findings noted in patients with late heart fail-
ure included normal LV size in the setting of a mean LV fractional shortening
<10%, as well as frequent pulmonary hypertension, increased pulmonary re-
sistance, and left atrial dilation. We wished to characterize the late outcome
of doxorubicin cardiotoxicity by reviewing the long-term echocardiographic
findings of this cohort. The remaining 79 of the original 115 patients have
had echocardiographic follow-up 11.1 years (mean) after completing doxoru-
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